Brain (Nervous System) CancersMILANONCT06899516
Project MILANO: Connections Between Patients With Brain Tumors and Their Pets: an Analysis of Concerns and Needs
An observational study of Brain (Nervous System) Cancers, run by Centre Hospitalier Universitaire de Saint Etienne at 1 site in France.
Trial summary
Context and problem In France, 61% of households own a pet, highlighting the significant role pets play in the daily lives. Patients diagnosed with brain tumors face specific challenges that may affect their ability to care their pets, including: Progressive neurological deficits (cognitive and/or motor), limiting… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Brain (Nervous System) Cancers
- What is being tested?
- The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)
- How many people
- 65 participants
- Where
- 1 siteFrance
- Study dates
- 20 Mar 2025to Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with a brain tumor who have one or more pets will be included.
Who may be able to join
- Patients diagnosed with a brain tumor.
- Patients who own at least one pet.
Who cannot join
- Patients who decline to participate in the study.
- Patients unable to complete the questionnaire.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Saint Etienne
Saint-Etienne, 42000
Carole Ramirez, Md, (0)477829326 ext. +33, carole.ramirez@chu-st-etienne.fr
Carole Ramirez, Md
About this study
Context and problem
In France, 61% of households own a pet, highlighting the significant role pets play in the daily lives. Patients diagnosed with brain tumors face specific challenges that may affect their ability to care their pets, including:
Read more
- Progressive neurological deficits (cognitive and/or motor), limiting their autonomy,
- A life-threatening prognosis.
In this context, the well-being of pets when their owner's health deteriorates becomes a critical concern. Indeed:
- Social isolation and the progressive loss of physical and cognitive abilities complicate pet care, particularly during prolonged hospitalizations or in the event of death,
- The lack of appropriate facilities and care solutions causes stress for pets, who are often unprepared for such transitions, and adds to the emotional burden on patients.
Why focus on patients with brain tumors?
- These patients have specific needs due to the rapid progression of their condition,
- A local study showed that 12% of patients with gliomas live alone, a significantly higher rate than in other cancer types. Patients who live alone are particularly exposed to issues related to their pet's future,
- Given the high morbidity and mortality associated with brain tumors, proactive planning for pet care is particularly urgent.
- Conditions
- Brain (Nervous System) Cancers
- Being tested
- The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)
- Keywords
- Brain tumors, Glioma patients, Pet care, Emotional burden
- Medical subject headings
- Neurologic Manifestations, Neoplasms, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)Other
The LAPS is a established tool for measuring the emotional bond between humans and their animal companions. Animal attachment is assessed according to three factors: the bond between owners and their dogs or cats, the closeness of the human-animal relationship, and the importance of the animal in the owner's life (Johnson et al., 1992). Higher scores indicate greater attachment.
| Study group | Role | What they receive |
|---|---|---|
| Pet-owning brain tumour patients | To assess the concerns and needs of patients with brain tumors regarding their pets, in order to plan for the pets' future when their owners are hospitalized, unable to care for them due to their condition, or in the event of their death. Receives: Other: The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992) |
What is being measured
The primary outcome is the main question the study is designed to answer.
LAPS scale
The Lexington Pet Attachment Scale (LAPS) measures the percentage of patients who are concerned about their pets. Values range from zero to one hundred, with higher scores indicating greater concern for pets.
Measured: Day 1
Secondary outcomes (1)
Questionnaire
A questionnaire that measures the percentage of patients who need more information and details of resources and support systems to help them with their pets.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2025
- Study start20 Mar 2025
- Primary completionMar 2026 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain (Nervous System) CancersStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de Saint EtienneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 65 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Carole Ramirez, Md, Principal investigator, CHU de SAINT-ETIENNE
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06899516
- Sponsor's protocol ID
- IRBN252025/CHUSTE
- Acronym
- MILANO
- Status last verified
- Mar 2025
- First submitted
- 21 Mar 2025
- Last updated
- 3 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Project MILANO: Connections Between Patients With Brain Tumors and Their Pets: an Analysis of Concerns and Needs
- ClinicalTrials.gov ID
- NCT06899516
- Acronym / sponsor ID
- MILANO / IRBN252025/CHUSTE
- Conditions
- Brain (Nervous System) Cancers
- Keywords
- Brain tumors, Glioma patients, Pet care, Emotional burden
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 65 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de Saint EtienneUniversity, hospital or other
- Study start
- 20 Mar 2025 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 28 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Context and problem
In France, 61% of households own a pet, highlighting the significant role pets play in the daily lives. Patients diagnosed with brain tumors face specific challenges that may affect their ability to care their pets, including:
- Progressive neurological deficits (cognitive and/or motor), limiting their autonomy,
- A life-threatening prognosis.
In this context, the well-being of pets when their owner's health deteriorates becomes a critical concern. Indeed:
- Social isolation and the progressive loss of physical and cognitive abilities complicate pet care, particularly during prolonged hospitalizations or in the event of death,
- The lack of appropriate facilities and care solutions causes stress for pets, who are often unprepared for such transitions, and adds to the emotional burden on patients.
Why focus on patients with brain tumors?
- These patients have specific needs due to the rapid progression of their condition,
- A local study showed that 12% of patients with gliomas live alone, a significantly higher rate than in other cancer types. Patients who live alone are particularly exposed to issues related to their pet's future,
- Given the high morbidity and mortality associated with brain tumors, proactive planning for pet care is particularly urgent.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pet-owning brain tumour patients | – | Other: The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)To assess the concerns and needs of patients with brain tumors regarding their pets, in order to plan for the pets' future when their owners are hospitalized, unable to care for them due to their condition, or in the event of their death. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with a brain tumor who have one or more pets will be included.
Key inclusion criteria (2 listed)
- Patients diagnosed with a brain tumor.
- Patients who own at least one pet.
Key exclusion criteria (2 listed)
- Patients who decline to participate in the study.
- Patients unable to complete the questionnaire.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)The LAPS is a established tool for measuring the emotional bond between humans and their animal companions. Animal attachment is assessed according to three factors: the bond between owners and their dogs or cats, the closeness of the human-animal relationship, and the importance of the animal in the owner's life (Johnson et al., 1992). Higher scores indicate greater attachment. | Other | Pet-owning brain tumour patients |
Primary outcome
LAPS scale
Time frame: Day 1
The Lexington Pet Attachment Scale (LAPS) measures the percentage of patients who are concerned about their pets. Values range from zero to one hundred, with higher scores indicating greater concern for pets.
1 secondary outcome
Questionnaire
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Brain (Nervous System) Cancers
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Recruiting
Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors
Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Carole Ramirez, Md principal investigator
CHU de SAINT-ETIENNE
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain (Nervous System) Cancers, run by Centre Hospitalier Universitaire de Saint Etienne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Carole Ramirez, Md ((0)477829326 ext. +33, carole.ramirez@chu-st-etienne.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LAPS scale (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2025.